Cyclopentyl Or Cyclopentene (e.g., Prostaglandins, Etc.) Patents (Class 514/573)
  • Patent number: 10925931
    Abstract: The invention is a pharmaceutical composition of human insulin or insulin analog that includes citrate, treprostinil and stabilizing agents, that has faster pharmacokinetic and/or pharmacodynamic action than commercial formulations of existing insulin analog products and that is stable for commercial use.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: February 23, 2021
    Assignee: Eli Lilly and Company
    Inventors: Michael Patrick Akers, Michael Edward Christe, Thomas Andrew Hardy, Ranajoy Majumdar, Chi Arch Nguyen, Chad Donald Paavola, Virender Kumar Sarin, Nanette Elizabeth Schulte
  • Patent number: 10556012
    Abstract: Described herein are compositions comprising a prostaglandin FP receptor agonist (PFPRA) compound and a fatty acid ester (e.g., isopropyl myristate), optionally comprising an ointment base such as a hydrocarbon base (e.g., petroleum jelly) and/or an organic alcohol (e.g., propylene glycol), that, when topically applied to the skin, locally delivers a therapeutically effective amount of the PFPRA compound to subcutaneous fat under the skin, and methods of preparation. The therapeutic effect is, for example, reduction of the subcutaneous fat under the skin. Further provided are methods of reducing body fat in a subject comprising topically administering the composition to the subject.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: February 11, 2020
    Assignee: Topokine Therapeutics, Inc.
    Inventors: Michael S. Singer, Murat V. Kalayoglu
  • Patent number: 10464878
    Abstract: The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: November 5, 2019
    Assignee: Corsair Pharma, Inc.
    Inventors: Xiaoming Zhang, Meenakshi S. Venkatraman, Cyrus K. Becker
  • Patent number: 10457623
    Abstract: The present invention relates to a novel process for preparing Lubiprostone and novel intermediates prepared from the process. The process of the present invention does not generate hydrogenated by-products that are difficult to be removed, and thus enables the production of Lubiprostone in an efficient and economical way.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: October 29, 2019
    Assignee: CHIROGATE INTERNATIONAL INC.
    Inventors: Shih-Yi Wei, Min-Kuan Hsu
  • Patent number: 10441627
    Abstract: This disclosure relates to a method of treating Prader-Willi Syndrome. The method includes administering to a patient in need thereof an effective amount of a composition containing a selective oxytocin receptor agonist or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: October 15, 2019
    Assignee: FERRING B.V.
    Inventors: Pascal Danglas, Michael Reidy, Paul Korner, Sudarkodi Alagarsamy
  • Patent number: 10342545
    Abstract: Disclosed are methods and devices for obtaining patent hemostasis of the radial artery by compressing the uninstrumented ulnar artery to increase radial artery flow. The device comprises a band having an inflatable bladder for applying blunt pressure to the ulnar artery. The method comprises applying a pressure to the homolateral ulnar artery and applying a pressure to the radial artery at the access site to obtain hemostasis at the access site. The method further comprises administering an anticoagulant to a patient at a dose ranging from about 20 units per kg of body weight to about 30 units per kg of body weight.
    Type: Grant
    Filed: September 18, 2018
    Date of Patent: July 9, 2019
    Assignee: VASO INNOVATIONS INC.
    Inventor: Samir Bipin Pancholy
  • Patent number: 10335418
    Abstract: Provided are methods, compositions, systems, and kits for treating metabolic syndrome or a disorder associated with metabolic syndrome, e.g., obesity, dyslipidemia, and/or a diabetic condition, comprising administering systemically to a subject one or more compounds of the Formula (I) and/or (II): or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, polymorph, tautomer, isotopically enriched derivative, or prodrug thereof, wherein , L, R1, R2, Z, X, A and B are defined herein.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: July 2, 2019
    Assignee: Topokine Therapeutics, Inc.
    Inventor: Murat V. Kalayoglu
  • Patent number: 10265372
    Abstract: Methods, pharmaceutical compositions, and kits are provided for treating a subject with an effective amount of an oxytocin receptor (OXTR) agonist and an effective amount of an ALK5 antagonist. In certain aspects, the OXTR agonist may be oxytocin or an oxytocin analog (e.g., a small molecule). The ALK 5 antagonist may be a small molecule, such as 2-(3-(6-Methyl-pyridin-2-yl)-1H-pyrazol-4-yl)-1,5-naphthyridine, LY2157299, A 83-01, D 4476, GW 788388, LY 364947, Rep Sox, SB 431542, SB 505124, SB 525334, or SD 208. In certain aspects, the amounts of the OXTR agonist and ALK5 antagonist may be sufficient to induce muscle regeneration and/or neural cell regeneration in the subject.
    Type: Grant
    Filed: August 12, 2015
    Date of Patent: April 23, 2019
    Assignee: The Regents of the University of California
    Inventors: Irina M. Conboy, David Vernon Schaffer, Hanadie Yousef, Michael J. Conboy, Wendy Cousin, Christian Elabd
  • Patent number: 10226418
    Abstract: A composition for topical application to a mucosal body site contains a combination of L-arginine, niacin, and a cooling compound. In one embodiment the composition contains from about 2% to about 7% by weight of a nitric oxide releasing substance selected from the group consisting of L-arginine, L-arginine salts and L-arginine derivatives. The composition also contains from about 0.05% to about 0.5% by weight niacin, and from about 0.1% to about 1% by weight of at least one compound capable of providing a sensation of cooling to the body site of application.
    Type: Grant
    Filed: May 12, 2014
    Date of Patent: March 12, 2019
    Assignee: Susie Q, LTD.
    Inventor: Jerry T. Holubec
  • Patent number: 10172922
    Abstract: The invention is a composition of human insulin or insulin analog that includes treprostinil and that has faster pharmacokinetic action than commercial formulations of existing insulin analog products.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: January 8, 2019
    Assignee: Eli Lilly and Company
    Inventors: Michael Edward Christe, Thomas Andrew Hardy
  • Patent number: 10123738
    Abstract: Methods and apparatus for diagnosing cardiovascular health in a patient by monitoring changes in skin redness levels, which is associated with perfusion and ability of circulatory system to adapt to physical exertion. Color detectors including colorimeters and spectrophotometers may be used to monitor and quantify skin color. Wet run solutions such as acetylcholine solutions may be applied to the skin area being monitored. Skin redness can be monitored during the course of exercise or a stress test, as well as during recovery. Wearable color detector devices can be worn by patients during exercise.
    Type: Grant
    Filed: July 3, 2017
    Date of Patent: November 13, 2018
    Inventor: Spyros Kokolis
  • Patent number: 10086001
    Abstract: The present invention provides compositions comprising a prostacyclin or prostacyclin analog, or a pharmaceutically acceptable salt thereof for use in preventing or treating cystic fibrosis. The invention also provides the use of a kit comprising a prostacyclin or prostacyclin analog for treating or preventing a condition associated with cystic fibrosis in a subject.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: October 2, 2018
    Assignee: SciPharm SaRL
    Inventors: Michael Freissmuth, Xaver Koenig, Christina Just
  • Patent number: 10045996
    Abstract: The invention provides novel pharmaceutical compositions for the treatment of increased intraocular pressure based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water-soluble prostaglandin analogues. The compositions can be administered topically into the eye. The invention further provides kits comprising such compositions.
    Type: Grant
    Filed: March 16, 2011
    Date of Patent: August 14, 2018
    Assignee: NOVALIQ GMBH
    Inventors: Bastian Theisinger, Sonja Theisinger, Bernhard Günther
  • Patent number: 9949738
    Abstract: Disclosed are methods and devices for obtaining patent hemostasis of the radial artery by compressing the uninstrumented ulnar artery to increase radial artery flow. The device comprises a band having an inflatable bladder for applying blunt pressure to the ulnar artery. The method comprises applying a pressure to the homolateral ulnar artery and applying a pressure to the radial artery at the access site to obtain hemostasis at the access site. The method further comprises administering an anticoagulant to a patient at a dose ranging from about 20 units per kg of body weight to about 30 units per kg of body weight.
    Type: Grant
    Filed: February 7, 2017
    Date of Patent: April 24, 2018
    Assignee: VASOINNOVATIONS, INC.
    Inventor: Samir Bipin Pancholy
  • Patent number: 9943520
    Abstract: Dry powder formulations for inhalation and their use in the treatment diseases and conditions. The formulation contains a uniform blend of a first spray-dried powder and a second spray-dried powder. The first spray-dried powder contains spray-dried particles of a therapeutically active ingredient dispersed in a pharmaceutically acceptable hydrophobic excipient. The second spray-dried powder contains spray-dried particles formed from a pharmaceutically acceptable hydrophobic excipient but are substantially free of any therapeutically active ingredient. The active ingredient in the first spray-dried powder is loaded sufficiently high to compensate for the second spray-dried powder being substantially free of any active ingredient. A process for preparing such formulations is also described.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: April 17, 2018
    Assignee: SUN PHARMA GLOBAL FZE
    Inventors: Celine Decaudin, Vincent Rogue
  • Patent number: 9856231
    Abstract: Tetrahydrothiophene and related heterocyclic analogs and related methods for GABA aminotransferase inactivation.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: January 2, 2018
    Assignee: Northwestern University
    Inventors: Richard B. Silverman, Hoang V. Le, Dustin D. Hawker
  • Patent number: 9849179
    Abstract: Described herein are compositions comprising a prostaglandin FP receptor agonist (PFPRA) compound and a fatty acid ester (e.g., isopropyl myristate), optionally comprising an ointment base such as a hydrocarbon base (e.g., petroleum jelly) and/or an organic alcohol (e.g., propylene glycol), that, when topically applied to the skin, locally delivers a therapeutically effective amount of the PFPRA compound to subcutaneous fat under the skin, and methods of preparation. The therapeutic effect is, for example, reduction of the subcutaneous fat under the skin. Further provided are methods of reducing body fat in a subject comprising topically administering the composition to the subject.
    Type: Grant
    Filed: May 1, 2015
    Date of Patent: December 26, 2017
    Assignee: Topokine Therapeutics, Inc.
    Inventors: Michael S. Singer, Murat V. Kalayoglu
  • Patent number: 9670141
    Abstract: Cyclopentene carboxylic acid-related compounds as GABA-AT inhibitors for treatment of various addictions, disorders and disease states.
    Type: Grant
    Filed: October 10, 2016
    Date of Patent: June 6, 2017
    Assignee: NORTHWESTERN UNIVERSITY
    Inventors: Richard B. Silverman, Kenji Takaya, Hoang V. Le, Jose I. Juncosa
  • Patent number: 9629852
    Abstract: The present invention relates to a pharmaceutical composition suitable for ophthalmic use comprising one or more prostaglandin derivatives or salts, a stabilizing amount of polyethylene glycol hydroxystearate and pharmaceutically acceptable vehicle.
    Type: Grant
    Filed: October 15, 2008
    Date of Patent: April 25, 2017
    Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
    Inventors: Ajay Jaysingh Khopade, Arindam Halder, Subhas Balaram Bhowmick
  • Patent number: 9492422
    Abstract: A therapeutic or prophylactic agent for diabetes includes a thiazolidine derivative as a PPAR-? agonist as an effective component which exhibits a reduced side effect of the PPAR-? agonist. The therapeutic or prophylactic agent for diabetes includes a particular IP agonist such as beraprost sodium (BPS), and a thiazolidine derivative such as pioglitazone or a pharmaceutically acceptable salt thereof. Since the therapeutic or prophylactic agent exhibits a sufficiently effective hypoglycemic action without being accompanied by side effects characteristic to PPAR-? agonists, the agent is useful as a highly safe and effective therapeutic or prophylactic agent for diabetes.
    Type: Grant
    Filed: November 12, 2010
    Date of Patent: November 15, 2016
    Assignees: Toray Industries, Inc., The University of Tokyo
    Inventors: Takehiro Takahashi, Hiroki Kumagai, Takashi Kadowaki, Naoto Kubota, Tetsuya Kubota
  • Patent number: 9486427
    Abstract: The present invention relates to novel methods, compositions and kits useful for the treatment of pulmonary diseases such as pulmonary arterial hypertension. In particular, aerosolisable compositions of iloprost are provided which are for use in inhalation therapy. The administration is by inhalation over a short period of time, which is patient-friendly, effective, and well tolerated. Inhalation may, for example, be achieved using an efficient nebulizer based on the vibrating mesh technology.
    Type: Grant
    Filed: September 12, 2013
    Date of Patent: November 8, 2016
    Assignee: Vectura GMBH
    Inventors: Tobias Gessler, Thomas Schmehl, Werner Seeger, Robert Voswinckel
  • Patent number: 9456980
    Abstract: The invention provides a latanoprost-containing aqueous pharmaceutical composition filled in a filter-equipped container, with the adsorption of latanoprost by the filter being prevented. In the latanoprost-containing aqueous pharmaceutical composition filled in the filter-equipped container, a nonionic surfactant is contained in the composition and the filter is made from at least one material selected from the group consisting of polyether sulfone, polyvinylidene fluoride, polycarbonate, and polytetrafluoroethylene.
    Type: Grant
    Filed: August 29, 2008
    Date of Patent: October 4, 2016
    Assignee: WAKAMOTO PHARMACEUTICAL CO., LTD.
    Inventors: Kohei Yoda, Satoshi Yamazaki, Emi Kawaguchi
  • Patent number: 9387214
    Abstract: The present invention is directed to a method of screening for a therapeutic agent useful for treating pulmonary hypertension comprising: contacting an erythrocyte with a candidate therapeutic agent; and detecting a presence or absence of erythrocyte-derived adenosine triphosphate, wherein a greater erythrocyte-derived adenosine triphosphate level indicates the candidate therapeutic agent has greater activity in treating pulmonary hypertension. Additionally, the present invention is directed to methods of treating pulmonary arterial hypertension by stimulating ATP release from erythrocytes through co-administration to a subject in need thereof an amount of a PDE5 inhibitor compound, and an amount of a prostacyclin compound.
    Type: Grant
    Filed: January 10, 2013
    Date of Patent: July 12, 2016
    Assignee: United Therapeutics Corporation
    Inventors: Randy Stephen Sprague, Alan Howard Stephenson, Mary Litchfield Ellsworth, Elizabeth A. Bowles
  • Patent number: 9290432
    Abstract: The subject of the invention is process the preparation of travoprost of formula (I) characterized by that the free acid of formula (II) is a.) activated with 2-chloro-1,3-dimethyl-imidazolinium chloride (DMC) and the resulting activated carboxylic acid intermediate is reacted with isopropyl alcohol, or b.) reacted with alkyl haloformate and the resulting mixed anhydride is reacted with isopropyl alcohol, or c.) activated with a straight or branched C1-8 dialkyl dicarbonate and reacted with isopropanol in the presence of water-free magnesium salt.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: March 22, 2016
    Assignee: CHINOIN GYÓGYSZER ÉS VEGYÉSZETI TERMÉKEK GYÁRA ZRT.
    Inventors: Zoltán Bischof, Ádám Bódis, Mária Kömüves-Mars, Gábor Havasi
  • Patent number: 9283231
    Abstract: The present embodiments provide for methods of treating elevated intraocular pressure or glaucoma using a sustained release medicament consisting of prostaglandin in benzyl benzoate that is injected intraocularly no more frequently than once every two months.
    Type: Grant
    Filed: January 30, 2014
    Date of Patent: March 15, 2016
    Assignee: Icon Bioscience, Inc.
    Inventors: Vernon G. Wong, Mae W. Hu, Glenn T. Huang
  • Patent number: 9126898
    Abstract: The present invention relates to a process for preparing a prostaglandin derivative and an intermediate therefor. In accordance with the present invention, the prostaglandin F (PGF) derivative can be efficiently prepared with high purity by removing the protecting group of a protected prostaglandin E (PGE) derivative obtained from conjugate addition and then stereoselectively reducing the ketone group on the cyclopentanone ring of the PGE derivative.
    Type: Grant
    Filed: March 11, 2010
    Date of Patent: September 8, 2015
    Assignee: YONSUNG FINE CHEMICAL CO., LTD.
    Inventors: Changyoung Oh, Kee Young Lee, Yong Hyun Kim, Jae Eun Joo
  • Patent number: 9089579
    Abstract: Provided are methods, compositions, systems, and kits for treating metabolic syndrome or a disorder associated with metabolic syndrome, e.g., obesity, dyslipidemia, and/or a diabetic condition, comprising administering systemically to a subject one or more compounds of the Formula (I) and/or (II): or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, polymorph, tautomer, isotopically enriched derivative, or prodrug thereof, wherein, L, R1; R2, Z, X, A and B are defined herein.
    Type: Grant
    Filed: January 18, 2012
    Date of Patent: July 28, 2015
    Assignee: Topokine Therapeutics, Inc.
    Inventor: Murat V. Kalayoglu
  • Patent number: 9066854
    Abstract: Compositions and methods for the treatment of premature ejaculation are provided wherein a composition comprising a topical anesthetic, a shear-thinning polymeric thickener, a lipophilic component that is selected from the group consisting of an aliphatic C1 to C8 alcohol, an aliphatic C8 to C30 ester, a liquid polyol and a mixture thereof, water and a buffer system that provides a buffered pH value for the composition in the range of about 3 to about 7.4 is administered to the penile meatus.
    Type: Grant
    Filed: August 20, 2014
    Date of Patent: June 30, 2015
    Assignee: NEXMED HOLDINGS, INC.
    Inventors: Mingqi Lu, Qin Wang, James L. Yeager, Y. Joseph Mo
  • Patent number: 9060929
    Abstract: Compositions and methods for the treatment of premature ejaculation are provided wherein a composition comprising a vasoactive prostaglandin, a topical anesthetic, a shear-thinning polymeric thickener, a lipophilic component that is selected from the group consisting of an aliphatic C1 to C8 alcohol, an aliphatic C8 to C30 ester, a liquid polyol and a mixture thereof, water and a buffer system that provides a buffered pH value for the composition in the range of about 3 to about 7.4 is administered to the penile meatus.
    Type: Grant
    Filed: August 20, 2014
    Date of Patent: June 23, 2015
    Assignee: NEXMED HOLDINGS, INC.
    Inventors: Y. Joseph Mo, Mingqi Lu, Qin Wang, James L. Yeager
  • Patent number: 9056044
    Abstract: Compositions and methods for the treatment of premature ejaculation are provided wherein a composition comprising a vasoactive prostaglandin, a topical anesthetic, a shear-thinning polymeric thickener, a lipophilic component that is selected from the group consisting of an aliphatic C1 to C8 alcohol, an aliphatic C8 to C30 ester, a liquid polyol and a mixture thereof, water and a buffer system that provides a buffered pH value for the composition in the range of about 3 to about 7.4 is administered to the penile meatus.
    Type: Grant
    Filed: August 20, 2014
    Date of Patent: June 16, 2015
    Assignee: NEXMED HOLDINGS, INC.
    Inventors: Y. Joseph Mo, Mingqi Lu, Qin Wang, James L. Yeager
  • Patent number: 9040584
    Abstract: Described herein are compositions comprising a prostaglandin FP receptor agonist (PFPRA) compound and a fatty acid ester (e.g., isopropyl myristate), optionally comprising an ointment base such as a hydrocarbon base (e.g., petroleum jelly) and/or an organic alcohol (e.g., propylene glycol), that, when topically applied to the skin, locally delivers a therapeutically effective amount of the PFPRA compound to subcutaneous fat under the skin, and methods of preparation. The therapeutic effect is, for example, reduction of the subcutaneous fat under the skin. Further provided are methods of reducing body fat in a subject comprising topically administering the composition to the subject.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: May 26, 2015
    Assignee: Topokine Therapeutics, Inc.
    Inventors: Michael S. Singer, Murat V. Kalayoglu
  • Publication number: 20150126609
    Abstract: Provided is a pharmaceutical composition including an 11-deoxy-prostaglandin compound represented by formula (I): and a fatty acid ester. By mixing the compound of formula (I) and a fatty acid ester, the compound of formula (I) will be stabilized.
    Type: Application
    Filed: January 6, 2015
    Publication date: May 7, 2015
    Applicants: SUCAMPO AG, R-TECH UENO, LTD.
    Inventors: Yasuhiro HARADA, Junichi KAWASAKI, Yoshie NISHIMURA, Ryuji UENO
  • Patent number: 9006290
    Abstract: The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, Syndrome X, thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: April 14, 2015
    Assignee: Esperion Therapeutics, Inc.
    Inventors: Jean-Louis Henri Dasseux, Carmen Daniela Oniciu
  • Patent number: 9005605
    Abstract: The specification discloses compositions and methods for treating a soft tissue defect of an individual.
    Type: Grant
    Filed: February 16, 2012
    Date of Patent: April 14, 2015
    Assignee: Allergan, Inc.
    Inventors: Dennis E. Van Epps, Guang-Liang Jiang, Wha Bin Im
  • Publication number: 20150057325
    Abstract: The present invention relates to novel uses of compounds that protect the endothelium, particularly prostacyclin and variants and derivatives thereof in the treatment or prevention of acute traumatic coagulopathy (ATC) and of patients resuscitating from cardiac arrest. The invention also relates to a method of identifying individuals at risk of developing ATC.
    Type: Application
    Filed: March 26, 2013
    Publication date: February 26, 2015
    Applicant: Rigshospitalet
    Inventors: Pär Johansson, Sisse Rye Ostrowski
  • Patent number: 8962688
    Abstract: The present invention relates to combined use of (a) a specific prostaglandin (PG) compound and (b) a H+,K+-ATPase inhibitor for the treatment of gastrointestinal disorders.
    Type: Grant
    Filed: April 11, 2006
    Date of Patent: February 24, 2015
    Assignee: Sucampo AG
    Inventor: Ryuji Ueno
  • Patent number: 8946291
    Abstract: A method of treating melanoma in a subject comprising administering an amount of SOX9 sufficient to treat melanoma is disclosed. A method of treating a hyperpigmentary condition in a subject comprising administering an amount of inhibitor of SOX9 activity sufficient to treat the condition is disclosed. A method of treating melanoma in a subject comprising administering an amount of SOX9 sufficient to treat melanoma is disclosed. A method of treating melanoma in a subject comprising increasing the amounts of retinoic acid and SOX9 in the subject by amounts sufficient to treat melanoma. A method of treating melanoma in a subject comprising administering an amount of prostaglandin D2 and retinoic acid sufficient to treat cancer is disclosed. A method of sensitizing a melanoma cell to RA comprising administering an amount of SOX9 sufficient to decrease PRAME expression is disclosed.
    Type: Grant
    Filed: August 15, 2008
    Date of Patent: February 3, 2015
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: Vincent J. Hearing, Thierry Passeron
  • Publication number: 20150023868
    Abstract: The present invention is directed to HIF inhibitors and methods of preventing cell proliferation, reducing inflammation, and treating an angiogenic disease or disorders.
    Type: Application
    Filed: February 21, 2014
    Publication date: January 22, 2015
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventors: Othon Iliopoulos, Michael Zimmer
  • Publication number: 20150018423
    Abstract: Formulations and methods for growing hone in a site specific location using an osteogenic molecule such as a prostaglandin, and a delivery vehicle which is preferably a polymer matrix.
    Type: Application
    Filed: October 2, 2014
    Publication date: January 15, 2015
    Inventors: Albert G. Prescott, Paul Odgren, Sandy Marks
  • Publication number: 20150018400
    Abstract: Disclosed herein is a method comprising administering a compound to a mammal suffering from an inflammatory bowel disease for the treatment of said disease, said compound having a structure according to Formula I wherein X, Y, B, R2, R3, R4, R5, R6 and n have the meanings found herein.
    Type: Application
    Filed: May 2, 2014
    Publication date: January 15, 2015
    Inventors: YARIV DONDE, JEREMIAH H. NGUYEN, KAREN M. KEDZIE, DANIEL W. GIL, JOHN E. DONELLO, WHA-BIN IM
  • Patent number: 8933120
    Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
    Type: Grant
    Filed: December 9, 2013
    Date of Patent: January 13, 2015
    Assignee: Allergan, Inc.
    Inventors: Chin-Ming Chang, James N. Chang, Rhett M. Schiffman, R. Scott Jordan, Joan-En Chang-Lin
  • Publication number: 20150011587
    Abstract: Compositions and methods for the treatment of premature ejaculation are provided wherein a composition comprising a topical anesthetic, a shear-thinning polymeric thickener, a lipophilic component that is selected from the group consisting of an aliphatic C1 to C8 alcohol, an aliphatic C8 to C30 ester, a liquid polyol and a mixture thereof, water and a buffer system that provides a buffered pH value for the composition in the range of about 3 to about 7.4 is administered to the penile meatus.
    Type: Application
    Filed: August 20, 2014
    Publication date: January 8, 2015
    Applicant: NEXMED HOLDINGS, INC.
    Inventors: Y. Joseph Mo, Mingqi Lu, Qin Wang, James L. Yeager
  • Publication number: 20150011638
    Abstract: Compositions and methods for the treatment of premature ejaculation are provided wherein a composition comprising a topical anesthetic, a shear-thinning polymeric thickener, a lipophilic component that is selected from the group consisting of an aliphatic C1 to C8 alcohol, an aliphatic C8 to C30 ester, a liquid polyol and a mixture thereof, water and a buffer system that provides a buffered pH value for the composition in the range of about 3 to about 7.4 is administered to the penile meatus.
    Type: Application
    Filed: August 20, 2014
    Publication date: January 8, 2015
    Applicant: NexMed Holdings, Inc.
    Inventors: Y. Joseph Mo, Qin Wang, James L. Yeager, Mingqi Lu
  • Patent number: 8926963
    Abstract: The specification discloses compositions and methods for treating a soft tissue defect of an individual.
    Type: Grant
    Filed: February 16, 2012
    Date of Patent: January 6, 2015
    Assignee: Allergan, Inc.
    Inventors: Dennis E. Van Epps, Guang-Liang Jiang, Adam L. Collette, Rebecca L. Horan, Jingsong Chen, Gregory H. Altman, Wha Bin Im
  • Publication number: 20140377337
    Abstract: The invention concerns the use of a preparation based on prostaglandin E1 (PGE1) as active ingredient in a carrier suitable for administration on the skin or on the mucous membranes, for the treatment by the transdermal or transmucosal route of acute or chronic ophthalmic pathologies of an ischemic nature, and in general for the treatment of ophthalmic pathologies involving at least in part an ischemic mechanism of the ocular district. By applying PGE1 on the skin, particularly in the form of a cream, it is possible to avoid the drawbacks of the intravenous administration of the drug, while still maintaining a comparable level of absorption of the drug in the ocular district. By suitably modulating the dosage, it is possible to obtain in the eye, by the cutaneous administration of PGE1, the same clinical results that can be obtained by intravenous administration.
    Type: Application
    Filed: February 4, 2013
    Publication date: December 25, 2014
    Inventor: Robert Davis STEIGERWALT, JR.
  • Patent number: 8916206
    Abstract: Drug-containing nanoparticles are provided that enable effective targeting and sustained-release of a water-soluble, non-peptide, low-molecular weight drug and cause reduced accumulation of the drug in the liver. The nanoparticles containing a water-soluble, non-peptide, low-molecular weight drug are obtained by hydrophobicizing the water-soluble, non-peptide, low-molecular weight drug by a metal ion, and reacting the hydrophobicized drug with a poly(lactic acid)-polyethylene glycol block copolymer or a poly(lactic-co-glycolic acid)-polyethylene glycol block copolymer. The nanoparticles have favorable targeting and sustained-release properties and cause reduced accumulation of the drug in the liver.
    Type: Grant
    Filed: November 29, 2006
    Date of Patent: December 23, 2014
    Assignee: LTT Bio-Pharma Co., Ltd.
    Inventors: Tsutomu Ishihara, Ayako Mizushima
  • Publication number: 20140371252
    Abstract: Processes for making and using compounds of formula (I): wherein R1, R2, R3, R4a, R4b, R5 and R6 are defined herein, as well as other indene derivatives are disclosed herein. These compounds are disclosed as being useful in treating inflammatory conditions or diseases.
    Type: Application
    Filed: January 23, 2014
    Publication date: December 18, 2014
    Applicant: Aquinox Pharmaceuticals Inc.
    Inventors: Jeffery R. Raymond, Kang Han, Yuanlin Zhou, Yuehua He, Bradley Noren, James Gee Ken Yee
  • Publication number: 20140350482
    Abstract: The present invention relates to methods for reconstituting and relates to reconstitution devices suitable for reconstituting many different materials. Furthermore, the present invention includes methods of treatment and methods of use related to a reconstitution device or apparatus. Some embodiments are suitable for reconstituting small amounts of a pharmaceutical compositions and using the pharmaceutical composition for the treatment of sexual dysfunction.
    Type: Application
    Filed: July 6, 2012
    Publication date: November 27, 2014
    Inventors: Bassam B. Damaj, Richard Martin, Michael Mueller, Daniel W. Frank
  • Publication number: 20140343107
    Abstract: The invention provides retinoic acid receptor (RAR) selective agonists and formulations thereof for the treatment of disease or for inducing a medically beneficial effect.
    Type: Application
    Filed: May 23, 2014
    Publication date: November 20, 2014
    Applicant: QuRetino Therapeutics, Inc.
    Inventor: Ferenc Makra
  • Patent number: 8883125
    Abstract: The invention relates to a cosmetic composition comprising, in a physiologically acceptable aqueous medium, a cucurbic acid compound of formula (I) in which R1 represents a radical COOR3, R3 denoting a hydrogen atom or a C1-C4 alkyl radical, optionally substituted with one or more hydroxyl groups; R2 represents a hydrocarbon-based radical containing from 1 to 18 carbon atoms; a homopolymer of a monomer comprising a sulfonic group; and a crosslinked acrylic acid homopolymer. Use for caring for and making up keratin materials.
    Type: Grant
    Filed: April 5, 2012
    Date of Patent: November 11, 2014
    Assignee: L'Oreal
    Inventors: Sophie Allemand, Marie Devie, Florence Levy